New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery

被引：30

作者：

Dyet, K ^{[1
]}

Devoy, A ^{[1
]}

McDowell, R ^{[1
]}

Martin, D ^{[1
]}

机构：

[1] Inst Environm Sci & Res, ESR, Porirua, New Zealand

来源：

VACCINE | 2005年 / 23卷 / 17-18期

关键词：

epidemic; meningococcal disease; strain B : 4 : P1.7b; 4;

D O I：

10.1016/j.vaccine.2005.01.050

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

New Zealand's epidemic of meningococcal disease began in mid 1991. Surveillance of meningococcal disease in New Zealand is based on a combination of disease notification and organism characterisation. Case numbers and population rates rose from 53 (1.5 per 100,000 population) in 1990 to a high of 650 (17.4 per 100,000 population) in 2001. The highest rates of disease occur in Pacific peoples under 20 years but the highest percentages of cases occur in Maori and European New Zealanders. The epidemic has been driven by a strain identified as B:4:P1.7b,4, ST-41/44 complex/Lineage III. The stability of the P1.7b,4 Por A protein has been demonstrated suggesting that the epidemic may be controlled by a strain-specific OMV vaccine. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：2228 / 2230

页数：3

共 10 条

[1] Household crowding a major risk factor for epidemic meningococcal disease in Auckland children [J].